SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
What does the latest WHO guideline reveal about GLP-1 obesity therapies, as released in December 2025? This landmark document establishes the first global standards for integrating glucagon-like peptide-1 (GLP-1) receptor agonists and GIP/GLP-1 dual agonists into chronic obesity management, treat...
Strengthening EU Pharmaceutical Supply Security Through the Critical Medicines Act
Enhancing EU Supply Security for Essential Pharmaceuticals
The EU's Critical Medicines Act proposal is a key initiative to strengthen EU pharmaceutical supply security amid ongoing shortages of vital drugs like antibiotics,...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufacturing and Innovation
Launching the Biomanufacturing Excellence Act of 2025
The Biomanufacturing Excellence Act of 2025, introduced as H.R. 6089 in the 119th Congress on ...